news
Novartis receives positive CHMP opinion for Ilaris®
"Novartis welcomes the decision by the CHMP in support of…
18 January 2013 | By Novartis
"Novartis welcomes the decision by the CHMP in support of the approval of Ilaris in the EU"
List view / Grid view
David Epstein
news
New analysis indicates that Novartis drug Gilenya shows significant early effect on reducing brain volume loss at 6 months
Gilenya® the first once-daily oral therapy...
12 October 2012 | By Novartis
Gilenya® the first once-daily oral therapy...
news
Novartis receives European Commission approval for once-daily Seebri® Breezhaler® as maintenance COPD treatment in the EU
Seebri® Breezhaler® approved...
1 October 2012 | By Novartis
Seebri® Breezhaler® approved...
news
Novartis data at ERS shows efficacy of once-daily COPD portfolio versus comparators, further establishes dual-bronchodilator QVA149
Further data from the COPD clinical trial programs...
3 September 2012 | By Novartis
Further data from the COPD clinical trial programs...
news
Novartis receives positive CHMP opinion for once-daily Seebri® Breezhaler® to treat COPD patients in the EU
CHMP has adopted a positive opinion for Seebri® Breezhaler®...
22 June 2012 | By Novartis
CHMP has adopted a positive opinion for Seebri® Breezhaler®...
news
Novartis to revise product information in the European Union for high blood pressure drug Rasilez®
CHMP concluded the risk-benefit review of Rasilez* (aliskiren)...
17 February 2012 | By Novartis
CHMP concluded the risk-benefit review of Rasilez* (aliskiren)...
news
Novartis receives approval for Lucentis® and launches Galvus® in China
Novartis has received regulatory approval in China from the SFDA…
18 January 2012 | By Novartis
Novartis has received regulatory approval in China from the SFDA for Lucentis® (ranibizumab)...
news
Novartis to restructure US business to strengthen competitive position in light of loss of Diovan® patent
US General Medicines restructuring results in reduction of 1,960 positions...
13 January 2012 | By Novartis
US General Medicines restructuring results in reduction of 1,960 positions...
news
Novartis drug Gilenya® showed positive clinical outcomes for relapsing-remitting MS patients in third large Phase III clinical trial
Once-daily oral MS medicine showed a 48% relative reduction in…
15 December 2011 | By Novartis
Once-daily oral MS medicine showed a 48% relative reduction in annualized relapse rate, meeting primary endpoint in Phase III placebo-controlled study...
news
Novartis gains European Commission approval for Rasitrio®
Rasitrio®, the first triple combination of aliskiren, amlodipine and hydrochlorothiazide…
28 November 2011 | By Novartis
Rasitrio®, the first triple combination of aliskiren, amlodipine and hydrochlorothiazide in a single pill has received approval...
news
Novartis Phase III study shows ACZ885 helped substantially reduce steroid use in 45% of patients with serious form of childhood arthritis
New pivotal Phase III data announced...
7 November 2011 | By Novartis
New pivotal Phase III data announced...
news
Novartis drug Gilenya® (fingolimod) shows up to 71% reduction in annualized relapse rates in MS patients
Novartis will showcase data from 13 abstracts on fingolimod (Gilenya®)...
17 October 2011 | By Novartis
Novartis will showcase data from 13 abstracts on fingolimod (Gilenya®)...
news
Novartis receives approval in Japan for two innovative therapies, Gilenya® in MS and Ilaris® in CAPS
Novartis has received regulatory approval in Japan for once-daily Gilenya…
27 September 2011 | By Novartis
Novartis has received regulatory approval in Japan for once-daily Gilenya (fingolimod)...
news
New data shows potential of respiratory portfolio to help COPD patients maintain active and productive lives
Novartis has presented new Phase III data at the ERS…
27 September 2011 | By Novartis
Novartis has presented new Phase III data at the ERS congress...
news
Novartis gains positive CHMP opinion for Rasitrio®
The CHMP adopted a positive opinion for Rasitrio® for the…
23 September 2011 | By Novartis
The CHMP adopted a positive opinion for Rasitrio® for the treatment of high blood pressure...
